Aktis Oncology CEO to Present at Jefferies Healthcare Conference
Event summary
- Aktis Oncology CEO Matthew Roden to present at Jefferies Global Healthcare Conference on June 3, 2026.
- Live webcast available via Aktis Investor Relations page.
- Archived replay accessible for 90 days post-conference.
- Aktis focuses on expanding targeted radiopharmaceuticals to broader patient populations.
- Company's pipeline includes AKY-1189 and AKY-2519, targeting multiple tumor types.
The big picture
Aktis Oncology's presentation at the Jefferies Global Healthcare Conference underscores its focus on expanding the reach of targeted radiopharmaceuticals. The company's proprietary miniprotein radioconjugate platform aims to address unmet needs across multiple solid tumors, positioning it in a rapidly evolving oncology landscape. With strategic collaborations and a robust pipeline, Aktis is poised to compete with established players in the radiopharmaceutical sector.
What we're watching
- Pipeline Progress
- How Aktis' miniprotein radioconjugate platform advances its clinical-stage programs AKY-1189 and AKY-2519.
- Strategic Partnerships
- Whether the collaboration with Eli Lilly will accelerate novel radioconjugate development.
- Market Positioning
- The pace at which Aktis can differentiate itself in the competitive radiopharmaceutical space.
Related topics